CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
ReCell Treatment +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02380612
NCT02380612N/ACompleted

Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries

Avita Medical·interventional·Posted Mar 5, 2015·Updated Jan 7, 2025

In Brief

A clinical study evaluating ReCell Treatment and Skin Graft for Burns. Completed, enrolled 30 participants across 7 sites.

Detailed Summary

This is a randomized, within-subject controlled study to compare the clinical performance of the ReCell device when used as an adjunct to meshed skin graft in subjects requiring skin grafts for closure of burn injuries. Co-primary effectiveness endpoints include: (1) confirmed treatment area closure (i.e., healing) prior to or at 8 weeks as assessed by a blinded evaluator, and (2) a comparison of the actual expansion ratio, computed as the ratio of measured treated area to the measured donor site area, achieved for the ReCell-treated and control treatment areas. Safety will be evaluated in terms of long-term durability, scar outcomes and treatment-related adverse events.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBurns
CountriesUnited States

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 5, 2015
Enrollment StartJan 26, 2015
Primary CompletionJan 21, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.3 years ago

Interventions

ReCell Treatmentdevice

Skin Graftprocedure